Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Roflumilast + Vemurafenib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Roflumilast | B9302-107|BY217|BYK20869|Daliresp|Zoryve | Roflumilast inhibits PDE4D, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (PMID: 39574163). | ||
Vemurafenib | Zelboraf | RO5185426|PLX4032 | RAF Inhibitor (Pan) 28 | Zelboraf (vemurafenib) inhibits BRAF V600E, wild-type BRAF, ARAF, and CRAF (PMID: 20179705), which may result in an inhibition of the MAPK signaling pathway resulting in a reduction of tumor cell proliferation (PMID: 20823850). Zelboraf (vemurafenib) is FDA approved for BRAF V600E-mutant melanoma and for BRAF V600-positive Erdheim-Chester disease (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | melanoma | sensitive | Roflumilast + Vemurafenib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with the combination of Roflumilast and Zelboraf (vemurafenib) inhibited colony formation and resulted in decreased spheroid size of melanoma cells harboring BRAF V600E in culture, and led to greater inhibition of tumor growth in a cell line xenograft model compared to Zelboraf (vemurafenib) alone (PMID: 39574163). | 39574163 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|